Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

被引：0
|
作者：
Massimo Gentile
Fortunato Morabito
Giovanni Del Poeta
Francesca Romana Mauro
Gianluigi Reda
Paolo Sportoletti
Luca Laurenti
Marta Coscia
Yair Herishanu
Anna Grazia Recchia
Marzia Varettoni
Roberta Murru
Annalisa Chiarenza
Adalgisa Condoluci
Riccardo Moia
Daniela Pietrasanta
Giacomo Loseto
Ugo Consoli
Ilaria Scortechini
Francesca Maria Rossi
Antonella Zucchetto
Vincenzo Fraticelli
Ernesto Vigna
Cirino Botta
Giovanni Tripepi
Graziella D’ Arrigo
Angela Rago
Ilaria Angeletti
Annalisa Biagi
Ilaria Del Giudice
Riccardo Bomben
Gian Matteo Rigolin
Davide Rossi
Francesco Di Raimondo
Gianluca Gaidano
Aaron Polliack
Antonio Cuneo
Robin Foà
Valter Gattei
机构：
[1] Hematology Unit AO of Cosenza,Biothecnology Research Unit
[2] AO of Cosenza,Hematology Oncology Department
[3] Augusta Victoria Hospital,Division of Hematology
[4] S. Eugenio Hospital and University of Tor Vergata,Division of Hematology, Department of Translational and Precision Medicine
[5] ‘Sapienza’ University,Division of Ematologia
[6] Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico di Milano,Centro di Ricerca Emato
[7] University of Perugia,Oncologica (CREO)
[8] Fondazione Universitaria Policlinico A Gemelli di Roma,Division of Hematology
[9] A.O.U. Città della Salute e della Scienza di Torino,Sourasky Medical Center, Institute of Hematology, and Sackler Faculty of Medicine
[10] Tel-Aviv University,Division of Haematology
[11] Fondazione IRCCS Policlinico San Matteo,Hematology and Stem Cell Transplantation Unit
[12] Ospedale A. Businco,Division of Hematology, Policlinico, Department of Surgery and Medical Specialties
[13] University of Catania,Division of Hematology
[14] Oncology Institute of Southern Switzerland,Division of Hematology, Department of Translational Medicine
[15] University of Eastern Piedmont,Division of Hematology
[16] Azienda Ospedaliera SS Arrigo e Biagio e Cesare Arrigo,Hematology and Cell Therapy Unit
[17] IRCCS-Istituto Tumori ‘Giovanni Paolo II’,Department of Hematology
[18] G. Garibaldi Hospital,Clinical and Experimental Onco
[19] Clinica di Ematologia Ospedali Riuniti,Hematology Unit
[20] Centro di Riferimento Oncologico di Aviano (CRO) IRCCS,Hematology Section, Department of Medical Sciences
[21] CNR-IFC,Department of Hematology
[22] Research Unit of Reggio Calabria,undefined
[23] UOSD Ematologia ASL Roma 1,undefined
[24] Reparto di Oncoematologia Azienda Ospedaliera Santa Maria di Terni,undefined
[25] University of Ferrara,undefined
[26] Hadassah-Hebrew University Medical Center,undefined
来源：
Leukemia | 2021年 / 35卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：235 / 238
页数：3
相关论文
共 50 条
  • [1] Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study
    Gentile, Massimo
    Morabito, Fortunato
    Del Poeta, Giovanni
    Mauro, Francesca Romana
    Reda, Gianluigi
    Sportoletti, Paolo
    Laurenti, Luca
    Coscia, Marta
    Herishanu, Yair
    Recchia, Anna Grazia
    Varettoni, Marzia
    Murru, Roberta
    Chiarenza, Annalisa
    Condoluci, Adalgisa
    Moia, Riccardo
    Pietrasanta, Daniela
    Loseto, Giacomo
    Consoli, Ugo
    Scortechini, Ilaria
    Rossi, Francesca Maria
    Zucchetto, Antonella
    Fraticelli, Vincenzo
    Vigna, Ernesto
    Botta, Cirino
    Tripepi, Giovanni
    D'Arrigo, Graziella
    Rago, Angela
    Angeletti, Ilaria
    Biagi, Annalisa
    Del Giudice, Ilaria
    Bomben, Riccardo
    Rigolin, Gian Matteo
    Rossi, Davide
    Di Raimondo, Francesco
    Gaidano, Gianluca
    Polliack, Aaron
    Cuneo, Antonio
    Foa, Robin
    Gattei, Valter
    [J]. LEUKEMIA, 2021, 35 (01) : 235 - 238
  • [2] External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/ Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study
    Gentile, Massimo
    Morabito, Fortunato
    Del Poeta, Giovanni
    Mauro, Francesca Romana
    Reda, Gianluigi
    Sportoletti, Paolo
    Laurenti, Luca
    Coscia, Marta
    Herishanu, Yair
    Recchia, Anna G.
    Varettoni, Marzia
    Murru, Roberta
    Chiarenza, Annalisa
    Condoluci, Adalgisa
    Moia, Riccardo
    Pietrasanta, Daniela
    Loseto, Giacomo
    Consoli, Ugo
    Scortechini, Ilaria
    Rossi, Francesca Maria
    Zucchetto, Antonella
    Vigna, Ernesto
    Tripepi, Giovanni
    Rago, Angela
    Angeletti, Ilaria
    Biagi, Annalisa
    Del Giudice, Ilaria
    Bomben, Riccardo
    Rigolin, Gian Matteo
    Rossi, Davide
    Di Raimondo, Francesco
    Gaidano, Gianluca
    Polliack, Aaron
    Cuneo, Antonio
    Foa, Robin
    Gattei, Valter
    [J]. BLOOD, 2019, 134
  • [3] IBRUTINIB IN THE MANAGEMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A REAL-LIFE MONOCENTRIC EXPERIENCE
    Albi, E.
    Del Papa, B.
    Dorillo, E.
    Aureli, P.
    Cantelmi, M. G.
    Zei, T.
    Ostini, R. Iacucci
    Ciurnelli, R.
    Falzetti, F.
    Sportoletti, P.
    [J]. HAEMATOLOGICA, 2017, 102 : 123 - 123
  • [4] Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study
    Visentin, Andrea
    Mauro, Francesca Romana
    Cibien, Francesca
    Vitale, Candida
    Reda, Gianluigi
    Fresa, Alberto
    Ciolli, Stefania
    Pietrasanta, Daniela
    Marchetti, Monia
    Murru, Roberta
    Gentile, Massimo
    Rigolin, Gian Matteo
    Quaglia, Francesca Maria
    Scarfo, Lydia
    Sportoletti, Paolo
    Pravato, Stefano
    Piazza, Francesco
    Coscia, Marta
    Laurenti, Luca
    Molica, Stefano
    Foa, Robin
    Cuneo, Antonio
    Trentin, Livio
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : E95 - E99
  • [5] Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study
    Morabito, Fortunato
    Tripepi, Giovanni
    Del Poeta, Giovanni
    Mauro, Francesca Romana
    Reda, Gianluigi
    Sportoletti, Paolo
    Laurenti, Luca
    Coscia, Marta
    Herishanu, Yair
    Varettoni, Marzia
    Murru, Roberta
    Chiarenza, Annalisa
    Visentin, Andrea
    Condoluci, Adalgisa
    Moia, Riccardo
    Pietrasanta, Daniela
    Loseto, Giacomo
    Consoli, Ugo
    Scortechini, Ilaria
    Rossi, Francesca Maria
    Zucchetto, Antonella
    Vigna, Ernesto
    Martino, Enrica Antonia
    Mendicino, Francesco
    Botta, Cirino
    Caracciolo, Daniele
    Cassin, Ramona
    D'Arrigo, Graziella
    Galimberti, Sara
    Rago, Angela
    Angeletti, Ilaria
    Biagi, Annalisa
    Del Giudice, Ilaria
    Bomben, Riccardo
    Neri, Antonino
    Fronza, Gilberto
    Cutrona, Giovanna
    Rossi, Davide
    Di Raimondo, Francesco
    Cuneo, Antonio
    Gaidano, Gianluca
    Polliack, Aaron
    Trentin, Livio
    Foa, Robin
    Ferrarini, Manlio
    Gattei, Valter
    Gentile, Massimo
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (05) : E168 - E171
  • [6] REAL-LIFE EFFECTIVENESS OF IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA
    Dominguez, L.
    Valera-Rubio, M.
    Madronal, Carrion, I
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S32 - S32
  • [7] Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Burger, Jan A.
    Ferrajoli, Alessandra
    Estrov, Zeev E.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Bose, Prithviraj
    Fowler, Nathan H.
    Kadia, Tapan M.
    Daver, Naval G.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    [J]. BLOOD, 2019, 134
  • [8] Covariation of psychological and inflammatory variables in patients with chronic lymphocytic leukemia receiving ibrutinib.
    Godiwala, Neha Niranjan
    Maddocks, Kami J.
    Westbrook, Travis
    Byrd, John C.
    Andersen, Barbara L.
    Johnson, Amy J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib within a Named Patient Program (NPP) in Italy. a Real-Life Retrospective Study
    Mauro, Francesca Romana
    Soddu, Stefano
    Frustaci, Annamaria Maria
    Orsucci, Lorella
    Motta, Marina
    Scarfo, Lydia
    Zinzani, Pier Luigi
    Falzetti, Franca
    Farina, Lucia
    Marasca, Roberto
    Cortelezzi, Agostino
    Carlo-Stella, Carmelo
    Molica, Stefano
    Coscia, Marta
    Zaja, Francesco
    Laurenti, Luca
    de Fabritiis, Paolo
    Gaidano, Gianluca
    Gobbi, Marco
    Tani, Monica
    Di Renzo, Nicola
    Fazi, Paola
    Vignetti, Marco
    Cuneo, Antonio
    Foa, Robin
    [J]. BLOOD, 2018, 132
  • [10] Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia
    Niemann, Carsten U.
    Levin, Mark-David
    Dubois, Julie
    Kersting, Sabina
    Enggaard, Lisbeth
    Veldhuis, Gerrit J.
    Mous, Rogier
    Mellink, Clemens H. M.
    Dobber, Johan A.
    Poulsen, Christian B.
    Frederiksen, Henrik
    Janssens, Ann
    Schjodt, Ida
    Dompeling, Ellen C.
    Ranti, Juha
    Mattsson, Mattias
    Bellido, Mar
    Tran, Hoa T. T.
    Nasserinejad, Kazem
    Kater, Arnon P.
    [J]. BLOOD, 2021, 137 (08) : 1117 - 1120
12345